AUTOIMMUNE BIOMARKERS COLLABORATIVE NETWORK

自身免疫生物标志物协作网络

• 批准号: 7380422
• 负责人: LARRY W MORELAND
• 金额: $ 0.05万
• 依托单位: UNIVERSITY OF ALABAMA AT BIRMINGHAM
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-03-01 至 2007-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7380422
• 关键词: AUTOIMMUNE; BIOMARKERS; COLLABORATIVE; NETWORK

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The overall objective of this part of the ABCoN study is to integrate a variety of cutting edge discovery technologies in order to discover novel biomarkers that will be clinically useful in rheumatoid arthritis (RA). The ABCoN study will attempt to enroll each participant in the CLEAR registry. The specific aims are: Specific Aim 1: To determine whether specific patterns of gene expression, cell surface phenotypes, and/or levels of plasma proteins are predictive of clinical and radiographic outcome at three years disease duration in RA. This question will be studied in the CLEAR cohort. Two distinct patient groups will be compared, based on outcome: 1) patients with no evidence of erosive disease at 3 years disease duration, and 2) patients with severe erosive disease at three years disease duration. Specific Aim 2: To apply the knowledge gained in specific Aim 1 to determine whether specific patterns of gene expression, cell surface phenotypes, and/or levels of plasma proteins are predictive of clinical and X-ray outcome at three years, in the setting of recent onset rheumatoid arthritis. This question will be studied in a cohort of 600 African-American patients with early onset rheumatoid arthritis. As in specific Aim 1, two distinct patient groups will be compared, based on outcome: A) patients with no evidence of erosive disease at 3 years and B) patients with severe erosive disease at 3 years.

这个子项目是利用由NIH/NCRR资助的中心拨款提供的资源的许多研究子项目之一。子项目和调查员(PI)可能从另一个NIH来源获得了主要资金，因此可能会出现在其他CRISE条目中。列出的机构是针对中心的，而不一定是针对调查员的机构。ABCON研究这一部分的总体目标是整合各种尖端发现技术，以发现将在类风湿性关节炎(RA)临床上有用的新生物标记物。ABCON研究将尝试将每个参与者登记在Clear注册中心。具体目标是：特定目标1：确定基因表达的特定模式、细胞表面表型和/或血浆蛋白水平是否可以预测RA患者三年病程的临床和放射学结果。这个问题将在明确的队列中进行研究。将根据结果比较两个不同的患者组：1)在病程3年内没有证据表明有腐蚀性疾病的患者，以及2)在病程3年内有严重腐蚀性疾病的患者。具体目标2：应用在具体目标1中获得的知识，以确定基因表达的特定模式、细胞表面表型和/或血浆蛋白水平是否可以预测最近发病的类风湿性关节炎患者三年内的临床和X光结果。这个问题将在600名患有早发性类风湿性关节炎的非裔美国人的队列中进行研究。在具体目标1中，将根据结果比较两个不同的患者组：A)在3年时没有证据表明有腐蚀性疾病的患者，B)在3年时有严重的腐蚀性疾病的患者。